IGC Pharma Inc
For the period ended Dec 31, 2023. Filed Feb 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 14, 2024
IGC$0.20-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine months Ended December 31, | ||||
|---|---|---|---|---|
| 2023 ($) | 2022 ($) | |||
| Cash flows from operating activities: | ||||
| Net loss | (10,115) | (7,476) | ||
| Adjustment to reconcile net loss to net cash: | ||||
| Depreciation and amortization | 473 | 504 | ||
| Common stock-based compensation and expenses, net | 1,433 | 2,260 | ||
| Impairment of assets | 3,358 | - | ||
| Other non-cash items | (42) | 39 | ||
| Changes in: | ||||
| Accounts receivables, net | 14 | (127) | ||
| Inventory | (8) | (200) | ||
| Deposits and advances | 169 | 656 | ||
| Claims and advances | 4 | (91) | ||
| Accounts payable | 117 | (516) | ||
| Accrued and other liabilities | (83) | (572) | ||
| Operating lease asset | 99 | 93 | ||
| Operating lease liability | (92) | (100) | ||
| Net cash used in operating activities | (4,673) | (5,530) | ||
| Cash flow from investing activities: | ||||
| Purchase of property, plant, and equipment | (123) | (305) | ||
| Sale of property, plant, and equipment | 42 | 544 | ||
| Investment in short term investments | 154 | (88) | ||
| Acquisition and filing cost of patents and rights | (67) | (144) | ||
| Net cash provided by investing activities | 6 | 7 | ||
| Cash flows from financing activities: | ||||
| Net proceeds from the issuance of common stock | 2,860 | 103 | ||
| Repayment of long-term loan | (3) | (2) | ||
| Net cash provided by financing activities | 2,857 | 101 | ||
| Effects of exchange rate changes on cash and cash equivalents | (8) | (93) | ||
| Net decrease in cash and cash equivalents | (1,818) | (5,515) | ||
| Cash and cash equivalents at the beginning of the period | 3,196 | 10,460 | ||
| Cash and cash equivalents at the end of the period | 1,378 | 4,945 | ||
| Supplementary information: | ||||
| Non-cash items: | ||||
| Common stock issued/granted for stock-based compensation, including patent acquisition | 1,433 | 2,260 | ||
| December 31, 2023, Form 10-Q
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.